The Role of Metformin and Colesevelam in Human GLP-1 Secretion

Phase 4CompletedNCT02050074

University Hospital, Gentofte, Copenhagen12 enrolled

Overview

Our primary hypothesis is that bile acid sequestrant colesevelam and the antidiabetic drug metformin potentiates the secretion of the gut hormone glucagon-like peptide 1 (GLP-1).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

QUADRUPLE

Enrollment

Conditions

Type 2 Diabetes

Interventions

ColesevelamDRUG

MetforminDRUG

PlaceboOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Normal hemoglobin * BMI \> 23kg/m2 * HbA1c \<9 % * Informed concent Exclusion Criteria: * Liver disease ( aspartate aminotransferase/alanine aminotransferase \>2 × reference value) * Chronic intestinal disease * History of liver and / or gallbladder disease * Nephropathy (se-creatinine \>110 µM and / or albuminuria) * Insulin or GLP-1-based antidiabetic treatment * History of cholecystectomy or surgical resection of bowel segment * BMI \<23kg/m2 or BMI \>35 kg/m2 * Pregnancy

Locations (1)

Diabetes Research Division, Department of Medicine, Gentofte Hospital

Hellerup, Copenhagen, Denmark

Outcomes

Primary Outcomes

Change in the gut hormone glucagon-like peptide 1 (GLP-1)

Time frame: 0-240 min

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.